Call Us: 1.800.873.5297

By

Volkswagen Offers Cash to Appease Consumers

According to Reuters, Volkswagen announced on Monday that it will offer a $1,000 cash package to certain U.S. diesel vehicle owners affected by the emissions scandal. The move is the automaker’s latest attempt to appease owners who have been frustrated by depreciating car values and how VW has not announced any plans to fix the […]

By

Law360 Reports GM Settles Second Faulty Ignition Switch Lawsuit; Documents Indicate Cover Up

According to Law360, millions of documents have allegedly been produced in a Georgia lawsuit showing General Motors engaged in a “massive cover up” to hide a deadly ignition switch defect. Brooke Melton was killed on her 29th birthday in 2010 when her car lost power and slid into an oncoming car. An expert engineer looked […]

By

Johnson & Johnson Subsidiary McNeil PPC Inc. Pleads Guilty to Selling Children’s Medicine Containing Metal Particles

According to Law360, a unit of the healthcare giant Johnson & Johnson pleaded guilty Tuesday to a federal criminal charge for selling infants’ and children’s medicine containing metal particles. The subsidiary—McNeil PPC Inc.—must pay a $20 million criminal fine and forfeit $5 million. Unsealed court documents say metal particles, including nickel, iron, and chromium, were […]

By

AstraZeneca Pays $7.9 Million for Alleged Violations of Anti-Kickback Laws

The Wall Street Journal reports that the drug manufacturer, AstraZeneca, will pay $7.9 million to the federal government over allegations that the manufacturer violated anti-kickback laws and attempted to defraud the federal, state, and local U.S. governments. The drugmaker is accused of paying kickbacks to a large Pharmacy Benefits Manager in exchange for a guarantee that […]

By

Pfizer Agrees to $400 Million Settlement in Class-Action Securities Lawsuit Involving Investors

The Wall Street Journal reports that Pfizer has agreed to pay $400 million to settle a class-action securities lawsuit alleging that the company illegally marketed several medications causing its investors to lose money, according to a filing with the United States Securities and Exchange Commission (SEC). The securities lawsuit alleged that Pfizer marketed several drugs […]

By

Effexor Plaintiffs Seek to Drop 40% of Lawsuits from MDL

Law360 reports that the plaintiffs in a multidistrict litigation involving Effexor, a depression and anxiety medication manufactured by Wyeth Pharmaceuticals Inc., have sought to dismiss 26 lawsuits targeting the Pfizer unit over the drug’s alleged risk of birth defects. The multidistrict litigation is In re: Effexor (Venlafaxine Hydrochloride) Products Liability Litigation, MDL 2458. Judge Cynthia […]

By

FDA Approves New Blood Thinning Medication Savaysa (Edoxaban)

The FDA announced that it has approved Savaysa (edoxaban), an anti-clotting drug manufactured by Tokyo-based Daiichi Sankyo and used to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problems. Savaysa has also been approved by the FDA to treat […]

By

JPML Will Hear Motion to Centralize Cases Involving Takata Airbags (MDL 2599) During January Session

On January 29, 2015, a hearing before the Judicial Panel on Multidistrict Litigation (JPML) will take place in Miami, Florida regarding the potential Takata Airbag MDL (In re: Takata Airbag Products Liability Litigation, MDL No. 2599). During this hearing, plaintiffs and defendants will present their arguments to the panel as to whether all federally-filed Takata […]

By

FDA Warns of Rare, But Potentially Fatal, Skin Reactions with Ziprasidone

On December 11, 2014, the Food and Drug Administration (FDA) issued a Drug Safety Communication warning that the antipsychotic drug Ziprasidone (brand name, Geodon), which is used to treat schizophrenia and bipolar disorder, is associated with rare, but potentially fatal, serious skin reactions that can affect other parts of the body. The FDA reports that […]

By

JPML Decides to Centralize Cases Involving Syngenta Corporation in Kansas (MDL 2591)

Law360 reports that the Judicial Panel on Multidistrict Litigation (JPML) has agreed to centralize 177 lawsuits filed against Syngenta Corporation in the District of Kansas (In re: Syngenta AG MIR162 Corn Litigation, MDL 2591). The JPML said that it chose the District of Kansas because it is “readily accessible”, and assigned the MDL to Judge […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.